Thursday, July 3, 2025 7/3/2025

Feasibility and Assessment of a Cascade Traceback Screening program - FACTS

Award Number: U01CA240747
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/01/2020
PERIOD OF PERFORMANCE END DATE: 05/31/2025

Group Awards By:

View Award Description

Feasibility and Assessment of a Cascade Traceback Screening program - FACTS - PROJECT SUMMARY Ovarian cancer is the deadliest gynecologic cancer, and the fifth leading cause of cancer death in US women. Despite guidelines recommending genetic testing for all women with ovarian cancer, fewer than one-quarter are tested. This project will focus on the feasibility and options for implementation of a Traceback cascade screening program through methods, culturally- appropriate language, and legal issues related to identifying probands and family members and successfully facilitating genetic testing in healthcare systems with currently available resources. Our Long-term goal is to create an effective Traceback program that is practical and sustainable in the real-world setting. The main objective of this project is to determine the acceptability, feasibility, and effectiveness of a Traceback cascade screening program in multiple populations and healthcare systems that will guide broader implementation. Our research question is in what organizational contexts and populations a Traceback program for proband identification and cascade screening of family members can be implemented, what would successful outcomes be for such programs, and what are the contextual, logistical, and legal barriers to be addressed? Our specific aims are to: 1) to explore a legal solution based on the privacy laws of all 50 states that may hinder or facilitate genetic testing of family members; 2) illuminate culturally appropriate language and communication strategies to inform women with ovarian cancer and their family members about the availability of genetic testing; 3) describe the effectiveness and feasibility of a Traceback cascade screening program in three healthcare systems; and 4) to explore the implementation outcomes related to a Traceback cascade program to provide guidance for broader dissemination of such a program.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2023	GEISINGER CLINIC	100 N ACADEMY AVE	DANVILLE	PA	17822	MONTOUR	USA	Cancer Cause and Prevention Research	001	4	2/12/2024	NON-COMPETING CONTINUATION	$0
2024	2023	GEISINGER CLINIC	100 N ACADEMY AVE	DANVILLE	PA	17822	MONTOUR	USA	Cancer Cause and Prevention Research	000	4	12/21/2023	NON-COMPETING CONTINUATION	$0
2024	2023	GEISINGER CLINIC	100 N ACADEMY AVE # MC4970	DANVILLE	PA	17822	MONTOUR	USA	Cancer Cause and Prevention Research	002	4	7/31/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $658,560 )
2023	2023	GEISINGER CLINIC	100 N ACADEMY AVE	DANVILLE	PA	17822	MONTOUR	USA	Cancer Cause and Prevention Research	001	4	5/26/2023	NON-COMPETING CONTINUATION	$658,560
2023	2022	GEISINGER CLINIC	100 N ACADEMY AVE	DANVILLE	PA	17822	MONTOUR	USA	Cancer Cause and Prevention Research	000	3	4/6/2023	NON-COMPETING CONTINUATION	$0
														Subtotal = $658,560

Issue Date FY: 2022 ( Subtotal = $884,052 )
2022	2022	GEISINGER CLINIC	100 N ACADEMY AVE	DANVILLE	PA	17822	MONTOUR	USA	Cancer Cause and Prevention Research	002	3	8/25/2022	NON-COMPETING CONTINUATION	$225,801
2022	2022	GEISINGER CLINIC	100 N ACADEMY AVE	DANVILLE	PA	17822	MONTOUR	USA	Cancer Cause and Prevention Research	001	3	5/25/2022	NON-COMPETING CONTINUATION	$658,251
2022	2021	GEISINGER CLINIC	100 N ACADEMY AVE	DANVILLE	PA	17822	MONTOUR	USA	Cancer Cause and Prevention Research	000	2	11/22/2021	NON-COMPETING CONTINUATION	$0
														Subtotal = $884,052

Issue Date FY: 2021 ( Subtotal = $670,622 )
2021	2021	GEISINGER CLINIC	100 N ACADEMY AVE	DANVILLE	PA	17822	MONTOUR	USA	Cancer Cause and Prevention Research	000	2	5/11/2021	NON-COMPETING CONTINUATION	$670,622
														Subtotal = $670,622

Issue Date FY: 2020 ( Subtotal = $703,016 )
2020	2020	GEISINGER CLINIC	100 N ACADEMY AVE	DANVILLE	PA	17822	MONTOUR	USA	Cancer Cause and Prevention Research	000	1	4/15/2020	NEW	$703,016
														Subtotal = $703,016

Grand Total All Awards = $2,916,250

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Feasibility and Assessment of a Cascade Traceback Screening program - FACTS

Award Number: U01CA240747

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/01/2020

PERIOD OF PERFORMANCE END DATE: 05/31/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer